Definition of Key Variables for the Induction of Optimal NY-ESO-1-Specific T Cells in HLA Transgene Mice

No Thumbnail Available
Files
There are no files associated with this item.
Date
2010
Authors
Johannsen, Alexandre
Genolet, Raphael
Luther, Sanjiv A.
Luescher, Immanuel F.
Editors
Contact
Journal ISSN
Electronic ISSN
ISBN
Bibliographical data
Publisher
Series
URI (citable link)
DOI (citable link)
10.4049/jimmunol.1001397
ArXiv-ID
International patent number
Link to the license
oops
EU project number
Project
Open Access publication
Collections
Biologie
Restricted until
Title in another language
Research Projects
Organizational Units
Journal Issue
Publication type
Journal article
Publication status
Published
Published in
The Journal of Immunology ; 185 (2010), 6. - pp. 3445-3455. - ISSN 0022-1767. - eISSN 1550-6606
Abstract
An attractive treatment of cancer consists in inducing tumor-eradicating CD8+ CTL specific for tumor-associated Ags, such as NY-ESO-1 (ESO), a strongly immunogenic cancer germ line gene-encoded tumor-associated Ag, widely expressed on diverse tumors. To establish optimal priming of ESO-specific CTL and to define critical vaccine variables and mechanisms, we used HLA-A2/DR1 H-2-/- transgenic mice and sequential immunization with immunodominant DR1- and A2-restricted ESO peptides. Immunization of mice first with the DR1-restricted ESO123-137 peptide and subsequently with mature dendritic cells (DCs) presenting this and the A2-restriced ESO157-165 epitope generated abundant, circulating, high-avidity primary and memory CD8+ T cells that efficiently killed A2/ESO157-165+ tumor cells. This prime boost regimen was superior to other vaccine regimes and required strong Th1 cell responses, copresentation of MHC class I and MHC class II peptides by the same DC, and resulted in upregulation of sphingosine 1-phosphate receptor 1, and thus egress of freshly primed CD8+ T cells from the draining lymph nodes into circulation. This well-defined system allowed detailed mechanistic analysis, which revealed that 1) the Th1 cytokines IFN-gamma and IL-2 played key roles in CTL priming, namely by upregulating on naive CD8+ T cells the chemokine receptor CCR5; 2) the inflammatory chemokines CCL4 (MIP-1beta) and CCL3 (MIP-1alpha) chemoattracted primed CD4+ T cells to mature DCs and activated, naive CD8+ T cells to DC-CD4 conjugates, respectively; and 3) blockade of these chemokines or their common receptor CCR5 ablated priming of CD8(+) T cells and upregulation of sphingosine 1-phosphate receptor 1. These findings provide new opportunities for improving T cell cancer vaccines.
Summary in another language
Subject (DDC)
570 Biosciences, Biology
Keywords
Conference
Review
undefined / . - undefined, undefined. - (undefined; undefined)
Cite This
ISO 690JOHANNSEN, Alexandre, Raphael GENOLET, Daniel LEGLER, Sanjiv A. LUTHER, Immanuel F. LUESCHER, 2010. Definition of Key Variables for the Induction of Optimal NY-ESO-1-Specific T Cells in HLA Transgene Mice. In: The Journal of Immunology. 185(6), pp. 3445-3455. ISSN 0022-1767. eISSN 1550-6606. Available under: doi: 10.4049/jimmunol.1001397
BibTex
@article{Johannsen2010-09-15Defin-36057,
  year={2010},
  doi={10.4049/jimmunol.1001397},
  title={Definition of Key Variables for the Induction of Optimal NY-ESO-1-Specific T Cells in HLA Transgene Mice},
  number={6},
  volume={185},
  issn={0022-1767},
  journal={The Journal of Immunology},
  pages={3445--3455},
  author={Johannsen, Alexandre and Genolet, Raphael and Legler, Daniel and Luther, Sanjiv A. and Luescher, Immanuel F.}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/36057">
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Johannsen, Alexandre</dc:contributor>
    <dcterms:title>Definition of Key Variables for the Induction of Optimal NY-ESO-1-Specific T Cells in HLA Transgene Mice</dcterms:title>
    <dc:language>eng</dc:language>
    <dc:creator>Luther, Sanjiv A.</dc:creator>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Genolet, Raphael</dc:creator>
    <dc:creator>Legler, Daniel</dc:creator>
    <dc:creator>Johannsen, Alexandre</dc:creator>
    <dc:contributor>Genolet, Raphael</dc:contributor>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:contributor>Luescher, Immanuel F.</dc:contributor>
    <dc:contributor>Legler, Daniel</dc:contributor>
    <dc:creator>Luescher, Immanuel F.</dc:creator>
    <dcterms:abstract xml:lang="eng">An attractive treatment of cancer consists in inducing tumor-eradicating CD8&lt;sup&gt;+&lt;/sup&gt; CTL specific for tumor-associated Ags, such as NY-ESO-1 (ESO), a strongly immunogenic cancer germ line gene-encoded tumor-associated Ag, widely expressed on diverse tumors. To establish optimal priming of ESO-specific CTL and to define critical vaccine variables and mechanisms, we used HLA-A2/DR1 H-2&lt;sup&gt;-/-&lt;/sup&gt; transgenic mice and sequential immunization with immunodominant DR1- and A2-restricted ESO peptides. Immunization of mice first with the DR1-restricted ESO&lt;sub&gt;123-137&lt;/sub&gt; peptide and subsequently with mature dendritic cells (DCs) presenting this and the A2-restriced ESO&lt;sub&gt;157-165&lt;/sub&gt; epitope generated abundant, circulating, high-avidity primary and memory CD8&lt;sup&gt;+&lt;/sup&gt; T cells that efficiently killed A2/ESO&lt;sub&gt;157-165&lt;/sub&gt;&lt;sup&gt;+&lt;/sup&gt; tumor cells. This prime boost regimen was superior to other vaccine regimes and required strong Th1 cell responses, copresentation of MHC class I and MHC class II peptides by the same DC, and resulted in upregulation of sphingosine 1-phosphate receptor 1, and thus egress of freshly primed CD8&lt;sup&gt;+&lt;/sup&gt; T cells from the draining lymph nodes into circulation. This well-defined system allowed detailed mechanistic analysis, which revealed that 1) the Th1 cytokines IFN-gamma and IL-2 played key roles in CTL priming, namely by upregulating on naive CD8&lt;sup&gt;+&lt;/sup&gt; T cells the chemokine receptor CCR5; 2) the inflammatory chemokines CCL4 (MIP-1beta) and CCL3 (MIP-1alpha) chemoattracted primed CD4&lt;sup&gt;+&lt;/sup&gt; T cells to mature DCs and activated, naive CD8&lt;sup&gt;+&lt;/sup&gt; T cells to DC-CD4 conjugates, respectively; and 3) blockade of these chemokines or their common receptor CCR5 ablated priming of CD8(+) T cells and upregulation of sphingosine 1-phosphate receptor 1. These findings provide new opportunities for improving T cell cancer vaccines.</dcterms:abstract>
    <dc:contributor>Luther, Sanjiv A.</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2016-11-23T14:49:51Z</dcterms:available>
    <dcterms:issued>2010-09-15</dcterms:issued>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/36057"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2016-11-23T14:49:51Z</dc:date>
  </rdf:Description>
</rdf:RDF>
Internal note
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Contact
URL of original publication
Test date of URL
Examination date of dissertation
Method of financing
Comment on publication
Alliance license
Corresponding Authors der Uni Konstanz vorhanden
International Co-Authors
Bibliography of Konstanz
No
Refereed